Compare Innodata Inc (INOD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Merck & Co., Inc. — how do they compare? Innodata Inc trades at $61.91 (market cap $2.10B), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 167.3× Innodata Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Merck & Co., Inc. for 98 Days on average.
| INOD | MRK | |
|---|---|---|
Market Cap | $2.10B | $351.28B |
Volume | 989,493 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $121.50 | $156.43 |
52-Week Low | $34.45 | $82.49 |
Typical Hold Time | 19 Days | 98 Days |
Enterprise Value | $1.86B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
